Coegin Pharma (COEGIN) Q1 2025 earnings summary

Executive summary

• Advanced launch preparations for Follicopeptide, targeting end-2025 market entry; strong partnership discussions ongoing in key markets including the US, Europe, Asia, and South America.

• Focused on cost reduction and production efficiency for Follicopeptide, with regulatory submission to the EU planned for Q3 2025.

• Positioned to capitalize on the longevity trend, with high demand for science-based hair growth and skin pigmentation solutions.

Financial highlights

• Net revenue was 0 TSEK for Q1 2025, unchanged from Q1 2024.

• Operating profit improved to -5,629 TSEK from -6,125 TSEK year-over-year.

• Earnings per share before and after dilution were -0.23 SEK, up from -0.61 SEK in Q1 2024.

• Cash at period end was 15,564 TSEK, down from 18,443 TSEK a year earlier.

• Cash flow for the period was -4,103 TSEK, compared to 12,890 TSEK in Q1 2024.

Outlook and guidance

• On track for Follicopeptide launch by end of 2025 and NPP-4 skin pigmentation product in 2026.

• Ongoing regulatory and production milestones, with EU documentation submission planned for Q3 2025.

• Continued focus on international partnerships and market expansion.